Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06514768
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-09
Brief Title:
JY231JY231 Injection for the Treatment of B-cell Acute Lymphoblastic LeukemiaB-ALL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
JY231 Injection for the Treatment of B-cell Acute Lymphoblastic LeukemiaB-ALL Early Exploratory Clinical Studies on Safety Tolerability and Initial Efficacy
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Early exploratory clinical study of the safety tolerability and initial efficacy of JY231 injection in the treatment of B-cell acute lymphoblastic leukemia B-ALL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None